New report highlights barriers to accessing Sativex across the UK
18 August 2021
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
How does MS affect dating and romantic relationships?
2 August 2021
This study took an in-depth look at the dating experiences of a small group of people living with MS.
Kesimpta (ofatumumab) approved for relapsing remitting MS in Scotland
12 July 2021
The MS Trust is delighted that Kesimpta (ofatumumab) has been approved by SMC for people with active relapsing remitting multiple sclerosis.
Stem cell transplants in the news
5 July 2021
Difficulties accessing NHS stem cell transplants (also known as HSCT or AHSCT) for multiple sclerosis were highlighted in national newspapers this weekend.
MS onset in childhood: do disease modifying drugs delay long term disability?
17 June 2021
Researchers have investigated how the risk of developing long term disability has changed over the last three decades for people whose MS begins in childhood.
Who gets MS and why?
17 May 2021
The number of people being diagnosed with multiple sclerosis around the world is increasing. In this article we take a look at recent research which investigates who might be more succeptible to multiple sclerosis and why that might be.
Ozanimod (Zeposia) - NICE says no in final decision
13 May 2021
The MS Trust is very disappointed that NICE is unable to recommend ozanimod as an NHS treatment for relapsing remitting MS in England and Wales.
Machine learning identifies new subtypes of MS from MRI scans
13 May 2021
Researchers have identified three new MRI-based subtypes are better able to predict MS activity, disability progression and treatment response than the standard relapsing and progressive subtypes.
Ofatumumab (Kesimpta) approved for relapsing MS in England and Wales
20 April 2021
The MS Trust is delighted that ofatumumab (Kesimpta) has been approved by NICE for people with active relapsing remitting multiple sclerosis.
Under-the-skin injection of Tysabri gets licence in UK and Ireland
16 April 2021
Under-the-skin (subcutaneous) injection of Tysabri (natalizumab) has been approved for UK and Ireland.
Ofatumumab (Kesimpta) gets UK licence for relapsing remitting MS
14 April 2021
The MHRA has granted marketing authorisation for ofatumumab (Kesimpta) for active relapsing remitting MS.
How long does it take for an MS drug to be fully effective?
31 March 2021
Researchers have investigated how long it takes for disease modifying drugs to be fully effective at reducing relapses and slowing progression.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.